Roche Holding AG Price, Forecast, Insider, Ratings, Fundamentals & Signals

San diego--(business wire)--vividion therapeutics, inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced a landmark publication in nature. the publication, “chemoproteomic discovery of a covalent allosteric inhibitor of wrn helicase,” by kristen baltgalvis et al, published jointly with our partner roche, speaks to the chemical prote.

Roche ceo thomas schinecker: “we had a strong start into the year, with both our divisions reporting high single digit growth in their base business – excluding covid-19 sales. after this quarter, the covid-19-related impact on sales is largely behind us. the appreciation of the swiss franc versus most currencies impacted sales reported in swiss francs compared to the same period last year. the uptake of our eye medicine vabysmo continues its momentum. we are pleased about the us approval of xolair as the first and only medicine for multiple food allergies. further, we recently received the us approval for alecensa in early-stage lung cancer. with an unprecedented 76% reduction in the risk of disease recurrence or death versus chemotherapy, alecensa significantly improves upon the standard of care for this specific form of lung cancer.

Basel, 19 april 2024 - roche (six: ro, rog; otcqx: rhhby) announced today that the u.s. food and drug administration (fda) has approved alecensa® (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) (tumours ≥ 4 cm or node positive), as detected by an fda-approved test. alecensa is now the first and only alk inhibitor approved for people with alk-positive early-stage nsclc who have undergone surgery to remove their tumour.

South san francisco, calif.--(business wire)--genentech, a member of the roche group (six: ro, rog; otcqx: rhhby), announced today that the u.s. food and drug administration (fda) has approved alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer (nsclc) (tumors ≥ 4 cm or node positive), as detected by an fda-approved test. alecensa is now the first and only alk inhibitor approved for people.

South san francisco, calif.--(business wire)--genentech, a member of the roche group (six: ro, rog; otcqx: rhhby), announced today data from the phase iii ocarina ii study (s31.006) of ocrevus® (ocrelizumab), an investigational twice-yearly, 10-minute subcutaneous (sc) injection. results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (rms or ppms) which reinforce the potential benefits of this investigat.

Vabysmo and Phesgo are still strong growth drivers for the company going forward, growing year over year in Q1 of 2024 by 108% and 70%, respectively. Mid-single digit sales growth is expected to remain with the pipeline that it has established thus far, with several data readouts expected in 2024 to drive additional shareholder value. Ocrevus is expected to remain as the best-selling Multiple Sclerosis Drug in 2030, generating approximately $6.3 billion in sales.

Roche Holding AG (OTCQX:RHHBY) Q1 2024 Sales/ Trading Statement Conference Call April 24, 2024 8:00 AM ET Company Participants Thomas Schinecker - Chief Executive Officer, Roche Group Alan Hippe - Chief Financial & Information Officer Teresa Graham - Chief Executive Officer, Roche Pharmaceuticals Matt Sause - Chief Executive Officer, Roche Diagnostics Bruno Eschli - Head, Investor Relations Conference Call Participants Richard Vosser - JPMorgan Emmanuel Papadakis - Deutsche Bank Simon Baker - Redburn Matthew Weston - UBS Luisa Hector - Berenberg Sachin Jain - Bank of America Andrew Baum - Citi Tim Anderson - Wolfe Research Steve Scala - Cowen Richard Parkes - BNP Emily Field - Barclays Mark Purcell - Morgan Stanley Peter Welford - Jefferies Thomas Schinecker Thank you very much and hello and welcome...

Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.

Swiss pharmaceutical giant Roche on Wednesday said falling sales of COVID-19 tests and medicines will stop having a “material impact” on its business after the first quarter of 2024 following the end of a boom during the pandemic.

Roche lowered its 2024 growth outlook in February as it continues to confront a drop-off in demand for its Covid-19 products and a number of its cancer drugs.

Roche said on Wednesday its first-quarter sales slipped 6% as the loss on COVID-19 related revenue was partly offset by further gains in eye drug Vabysmo.

Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.

Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.

David Roche, president and global strategist at Independent Strategy, discusses Iran's drone and missile attack on Israel and says "you have all degrees of escalation that are possible, but escalation you will get — there's no doubt about that."

A Roche-Lilly collaboration to test for indications of Alzheimer's disease won FDA Breakthrough Device Designation on Thursday. The new test will now proceed to clinical trials needed for full FDA approval.